A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer

Wuhan University200 enrolled

Overview

The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Recurrent Ovarian Cancer

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age between 18 and 70 years old 2. singed the information consent form 3. Expected survival time \>3 months 4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications. Exclusion Criteria: 1. Recurrence within 6 months after receiving initial platinum-based chemotherapy 2. without radiographic evidence for tumor recurrence 3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy

Locations (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Outcomes

Primary Outcomes

Evidence of the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.

Blood routine, urine routine, hepatic and kidney function, electrolyte, ECG, CT,MRI

Time frame: from pre-chemotherapy to 4-6 weeks post-chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.